KRAS and lung cancer: In a genetically-engineered mouse model of K-Ras-driven lung cancer, the expression of doxycycline-inducible dominant negative ATG4B C74A resulted in a strong reduction in lung cancer cell growth [36], suggesting that inhibition of ATG4B is a promising strategy for treatment of lung cancer.